Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Equity Premium Income ETF (JEPI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

JPMorgan Equity Premium Income ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

JPMorgan Equity Premium Income ETF vs Regeneron Pharmaceuticals Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.84, while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while JPMorgan Equity Premium Income ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

JEPIREGN
Sector
Income / Options OverlayHealth
52-Week High
$59.88$812.27
52-Week Low
$55.29$555.51
Market Cap
$82.06B
Enterprise Value
$76.77B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Equity Premium Income ETF

JEPI trades at $57.58, showing minimal daily change. Technical indicators are bullish overall, with strong moving average support but a neutral oscillator reading. Recent news highlights its role in income strategies, though some articles note underperformance versus peers. The ETF's covered-call strategy provides monthly income but may limit capital appreciation.

The outlook is mixed: JEPI offers reliable income with a covered-call approach, appealing for risk-averse investors. However, competition from higher-yielding ETFs and potential tax inefficiencies pose risks. Investors should weigh income stability against growth opportunity costs in a rising market.

Regeneron Pharmaceuticals Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Equity Premium Income ETF

JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.

Read more on JEPI

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN